Therefore, anti-EGFR antibody treatment was only indicated when patients had no mutations in KRAS or BRAF until recently, combination treatment of cetuximab with encorafenib and binimetinib was approved for the treatment of patients with metastatic colorectal cancer harboring a BRAF V600 E mutation [42]. Here, EGFR is linked to metastatic colorectal cancer.